Global Neutropenia Treatment
Global Neutropenia Treatment

Neutropenia Treatment Comprehensive Study by Type (Granulocyte -colony-stimulating factor (G-CSF), Antibiotics, Antifungal drugs), Disease Type (Cyclic neutropenia, Kostmannís syndrome, Chronic idiopathic neutropenia, Myelokathexis, Autoimmune neutropenia, Shwachman-Diamond syndrome, Isoimmune neonatal neutropenia), End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) Players and Region - Global Market Outlook to 2026

Neutropenia Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 239 Pages 212 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Neutropenia Treatment Market?

Neutropenia is a condition in which the number of neutrophils (a type of white blood cell) in the bloodstream is decreased (lower than normal level of neutrophils), affecting the body's ability to fight off infections. Depending on the severity it can be classified as mild, moderate, or severe, depending on the number of neutrophils in a sample of blood. It creates the main complication of an increased risk of infection.

The market study is being classified by Type (Granulocyte -colony-stimulating factor (G-CSF), Antibiotics and Antifungal drugs) and major geographies with country level break-up.

Kyowa Hakko Kirin Co., Ltd. (Japan), Cellerant Therapeutics (United States), Mylan N.V. (United States), Amgen (United States(, BeyondSpring (United States), Novartis AG (Switzerand), Pfizer (United States), Spectrum Pharmaceuticals (United States), Teva Pharmaceutical Industries Ltd. (Israel) and Myelo Therapeutics GmbH (Germany) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Neutropenia Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Neutropenia Treatment market by Type, Application and Region.

On the basis of geography, the market of Neutropenia Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Prevalence of Neutropenia
  • Rise in the Number of Hospitals and Clinics

Market Trend
  • Increasing Awareness about Neutropenia Treatment

Restraints
  • High Cost of Neutropenia Treatment

Opportunities
  • Growth in the Healthcare Industry Worldwide
  • Increasing Number of Online Pharmacies

Challenges
  • Stringent Government Rules and Regualtions





Key Target Audience
Neutropenia Treatment Providers, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Granulocyte -colony-stimulating factor (G-CSF)
  • Antibiotics
  • Antifungal drugs
By Disease Type
  • Cyclic neutropenia
  • Kostmannís syndrome
  • Chronic idiopathic neutropenia
  • Myelokathexis
  • Autoimmune neutropenia
  • Shwachman-Diamond syndrome
  • Isoimmune neonatal neutropenia

By End-users
  • Hospitals
  • Clinics
  • Others

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Neutropenia
      • 3.2.2. Rise in the Number of Hospitals and Clinics
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regualtions
    • 3.4. Market Trends
      • 3.4.1. Increasing Awareness about Neutropenia Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neutropenia Treatment, by Type, Disease Type, End-users, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Neutropenia Treatment (Value)
      • 5.2.1. Global Neutropenia Treatment by: Type (Value)
        • 5.2.1.1. Granulocyte -colony-stimulating factor (G-CSF)
        • 5.2.1.2. Antibiotics
        • 5.2.1.3. Antifungal drugs
      • 5.2.2. Global Neutropenia Treatment by: Disease Type (Value)
        • 5.2.2.1. Cyclic neutropenia
        • 5.2.2.2. Kostmannís syndrome
        • 5.2.2.3. Chronic idiopathic neutropenia
        • 5.2.2.4. Myelokathexis
        • 5.2.2.5. Autoimmune neutropenia
        • 5.2.2.6. Shwachman-Diamond syndrome
        • 5.2.2.7. Isoimmune neonatal neutropenia
      • 5.2.3. Global Neutropenia Treatment by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Neutropenia Treatment by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacy
        • 5.2.4.2. Retail Pharmacy
        • 5.2.4.3. Online Pharmacy
      • 5.2.5. Global Neutropenia Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Neutropenia Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Kyowa Hakko Kirin Co., Ltd. (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cellerant Therapeutics (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mylan N.V. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Amgen (United States(
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BeyondSpring (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerand)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Spectrum Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Myelo Therapeutics GmbH (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Neutropenia Treatment Sale, by Type, Disease Type, End-users, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Neutropenia Treatment (Value)
      • 7.2.1. Global Neutropenia Treatment by: Type (Value)
        • 7.2.1.1. Granulocyte -colony-stimulating factor (G-CSF)
        • 7.2.1.2. Antibiotics
        • 7.2.1.3. Antifungal drugs
      • 7.2.2. Global Neutropenia Treatment by: Disease Type (Value)
        • 7.2.2.1. Cyclic neutropenia
        • 7.2.2.2. Kostmannís syndrome
        • 7.2.2.3. Chronic idiopathic neutropenia
        • 7.2.2.4. Myelokathexis
        • 7.2.2.5. Autoimmune neutropenia
        • 7.2.2.6. Shwachman-Diamond syndrome
        • 7.2.2.7. Isoimmune neonatal neutropenia
      • 7.2.3. Global Neutropenia Treatment by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Neutropenia Treatment by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacy
        • 7.2.4.2. Retail Pharmacy
        • 7.2.4.3. Online Pharmacy
      • 7.2.5. Global Neutropenia Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neutropenia Treatment: by Type(USD Million)
  • Table 2. Neutropenia Treatment Granulocyte -colony-stimulating factor (G-CSF) , by Region USD Million (2015-2020)
  • Table 3. Neutropenia Treatment Antibiotics , by Region USD Million (2015-2020)
  • Table 4. Neutropenia Treatment Antifungal drugs , by Region USD Million (2015-2020)
  • Table 5. Neutropenia Treatment: by Disease Type(USD Million)
  • Table 6. Neutropenia Treatment Cyclic neutropenia , by Region USD Million (2015-2020)
  • Table 7. Neutropenia Treatment Kostmannís syndrome , by Region USD Million (2015-2020)
  • Table 8. Neutropenia Treatment Chronic idiopathic neutropenia , by Region USD Million (2015-2020)
  • Table 9. Neutropenia Treatment Myelokathexis , by Region USD Million (2015-2020)
  • Table 10. Neutropenia Treatment Autoimmune neutropenia , by Region USD Million (2015-2020)
  • Table 11. Neutropenia Treatment Shwachman-Diamond syndrome , by Region USD Million (2015-2020)
  • Table 12. Neutropenia Treatment Isoimmune neonatal neutropenia , by Region USD Million (2015-2020)
  • Table 13. Neutropenia Treatment: by End-users(USD Million)
  • Table 14. Neutropenia Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 15. Neutropenia Treatment Clinics , by Region USD Million (2015-2020)
  • Table 16. Neutropenia Treatment Others , by Region USD Million (2015-2020)
  • Table 17. Neutropenia Treatment: by Distribution Channel(USD Million)
  • Table 18. Neutropenia Treatment Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 19. Neutropenia Treatment Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 20. Neutropenia Treatment Online Pharmacy , by Region USD Million (2015-2020)
  • Table 21. South America Neutropenia Treatment, by Country USD Million (2015-2020)
  • Table 22. South America Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 23. South America Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 24. South America Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 25. South America Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 26. Brazil Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 27. Brazil Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 28. Brazil Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 29. Brazil Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 30. Argentina Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 31. Argentina Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 32. Argentina Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 33. Argentina Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 34. Rest of South America Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 35. Rest of South America Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 36. Rest of South America Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 37. Rest of South America Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 38. Asia Pacific Neutropenia Treatment, by Country USD Million (2015-2020)
  • Table 39. Asia Pacific Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 40. Asia Pacific Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 41. Asia Pacific Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 42. Asia Pacific Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 43. China Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 44. China Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 45. China Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 46. China Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 47. Japan Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 48. Japan Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 49. Japan Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 50. Japan Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 51. India Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 52. India Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 53. India Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 54. India Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 55. South Korea Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 56. South Korea Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 57. South Korea Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 58. South Korea Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 59. Taiwan Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 60. Taiwan Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 61. Taiwan Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 62. Taiwan Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 63. Australia Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 64. Australia Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 65. Australia Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 66. Australia Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 71. Europe Neutropenia Treatment, by Country USD Million (2015-2020)
  • Table 72. Europe Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 73. Europe Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 74. Europe Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 75. Europe Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 76. Germany Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 77. Germany Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 78. Germany Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 79. Germany Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 80. France Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 81. France Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 82. France Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 83. France Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 84. Italy Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 85. Italy Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 86. Italy Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 87. Italy Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 88. United Kingdom Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 89. United Kingdom Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 90. United Kingdom Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 91. United Kingdom Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 92. Netherlands Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 93. Netherlands Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 94. Netherlands Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 95. Netherlands Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 96. Rest of Europe Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 97. Rest of Europe Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 98. Rest of Europe Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 99. Rest of Europe Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 100. MEA Neutropenia Treatment, by Country USD Million (2015-2020)
  • Table 101. MEA Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 102. MEA Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 103. MEA Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 104. MEA Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 105. Middle East Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 106. Middle East Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 107. Middle East Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 108. Middle East Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 109. Africa Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 110. Africa Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 111. Africa Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 112. Africa Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 113. North America Neutropenia Treatment, by Country USD Million (2015-2020)
  • Table 114. North America Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 115. North America Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 116. North America Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 117. North America Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 118. United States Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 119. United States Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 120. United States Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 121. United States Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 122. Canada Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 123. Canada Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 124. Canada Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 125. Canada Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 126. Mexico Neutropenia Treatment, by Type USD Million (2015-2020)
  • Table 127. Mexico Neutropenia Treatment, by Disease Type USD Million (2015-2020)
  • Table 128. Mexico Neutropenia Treatment, by End-users USD Million (2015-2020)
  • Table 129. Mexico Neutropenia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Neutropenia Treatment: by Type(USD Million)
  • Table 141. Neutropenia Treatment Granulocyte -colony-stimulating factor (G-CSF) , by Region USD Million (2021-2026)
  • Table 142. Neutropenia Treatment Antibiotics , by Region USD Million (2021-2026)
  • Table 143. Neutropenia Treatment Antifungal drugs , by Region USD Million (2021-2026)
  • Table 144. Neutropenia Treatment: by Disease Type(USD Million)
  • Table 145. Neutropenia Treatment Cyclic neutropenia , by Region USD Million (2021-2026)
  • Table 146. Neutropenia Treatment Kostmannís syndrome , by Region USD Million (2021-2026)
  • Table 147. Neutropenia Treatment Chronic idiopathic neutropenia , by Region USD Million (2021-2026)
  • Table 148. Neutropenia Treatment Myelokathexis , by Region USD Million (2021-2026)
  • Table 149. Neutropenia Treatment Autoimmune neutropenia , by Region USD Million (2021-2026)
  • Table 150. Neutropenia Treatment Shwachman-Diamond syndrome , by Region USD Million (2021-2026)
  • Table 151. Neutropenia Treatment Isoimmune neonatal neutropenia , by Region USD Million (2021-2026)
  • Table 152. Neutropenia Treatment: by End-users(USD Million)
  • Table 153. Neutropenia Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 154. Neutropenia Treatment Clinics , by Region USD Million (2021-2026)
  • Table 155. Neutropenia Treatment Others , by Region USD Million (2021-2026)
  • Table 156. Neutropenia Treatment: by Distribution Channel(USD Million)
  • Table 157. Neutropenia Treatment Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 158. Neutropenia Treatment Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 159. Neutropenia Treatment Online Pharmacy , by Region USD Million (2021-2026)
  • Table 160. South America Neutropenia Treatment, by Country USD Million (2021-2026)
  • Table 161. South America Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 162. South America Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 163. South America Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 164. South America Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 165. Brazil Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 166. Brazil Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 167. Brazil Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 168. Brazil Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 169. Argentina Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 170. Argentina Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 171. Argentina Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 172. Argentina Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 173. Rest of South America Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 174. Rest of South America Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 175. Rest of South America Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 176. Rest of South America Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 177. Asia Pacific Neutropenia Treatment, by Country USD Million (2021-2026)
  • Table 178. Asia Pacific Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 179. Asia Pacific Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 180. Asia Pacific Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 181. Asia Pacific Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 182. China Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 183. China Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 184. China Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 185. China Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 186. Japan Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 187. Japan Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 188. Japan Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 189. Japan Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 190. India Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 191. India Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 192. India Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 193. India Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 194. South Korea Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 195. South Korea Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 196. South Korea Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 197. South Korea Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 198. Taiwan Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 199. Taiwan Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 200. Taiwan Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 201. Taiwan Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 202. Australia Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 203. Australia Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 204. Australia Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 205. Australia Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 209. Rest of Asia-Pacific Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 210. Europe Neutropenia Treatment, by Country USD Million (2021-2026)
  • Table 211. Europe Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 212. Europe Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 213. Europe Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 214. Europe Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 215. Germany Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 216. Germany Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 217. Germany Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 218. Germany Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 219. France Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 220. France Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 221. France Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 222. France Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 223. Italy Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 224. Italy Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 225. Italy Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 226. Italy Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 227. United Kingdom Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 228. United Kingdom Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 229. United Kingdom Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 230. United Kingdom Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 231. Netherlands Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 232. Netherlands Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 233. Netherlands Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 234. Netherlands Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 235. Rest of Europe Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 236. Rest of Europe Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 237. Rest of Europe Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 238. Rest of Europe Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 239. MEA Neutropenia Treatment, by Country USD Million (2021-2026)
  • Table 240. MEA Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 241. MEA Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 242. MEA Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 243. MEA Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 244. Middle East Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 245. Middle East Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 246. Middle East Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 247. Middle East Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 248. Africa Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 249. Africa Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 250. Africa Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 251. Africa Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 252. North America Neutropenia Treatment, by Country USD Million (2021-2026)
  • Table 253. North America Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 254. North America Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 255. North America Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 256. North America Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 257. United States Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 258. United States Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 259. United States Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 260. United States Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 261. Canada Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 262. Canada Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 263. Canada Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 264. Canada Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 265. Mexico Neutropenia Treatment, by Type USD Million (2021-2026)
  • Table 266. Mexico Neutropenia Treatment, by Disease Type USD Million (2021-2026)
  • Table 267. Mexico Neutropenia Treatment, by End-users USD Million (2021-2026)
  • Table 268. Mexico Neutropenia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neutropenia Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Neutropenia Treatment: by Disease Type USD Million (2015-2020)
  • Figure 6. Global Neutropenia Treatment: by End-users USD Million (2015-2020)
  • Figure 7. Global Neutropenia Treatment: by Distribution Channel USD Million (2015-2020)
  • Figure 8. South America Neutropenia Treatment Share (%), by Country
  • Figure 9. Asia Pacific Neutropenia Treatment Share (%), by Country
  • Figure 10. Europe Neutropenia Treatment Share (%), by Country
  • Figure 11. MEA Neutropenia Treatment Share (%), by Country
  • Figure 12. North America Neutropenia Treatment Share (%), by Country
  • Figure 13. Global Neutropenia Treatment share by Players 2020 (%)
  • Figure 14. Global Neutropenia Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Neutropenia Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Kyowa Hakko Kirin Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 18. Kyowa Hakko Kirin Co., Ltd. (Japan) Revenue: by Geography 2020
  • Figure 19. Cellerant Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 20. Cellerant Therapeutics (United States) Revenue: by Geography 2020
  • Figure 21. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 23. Amgen (United States( Revenue, Net Income and Gross profit
  • Figure 24. Amgen (United States( Revenue: by Geography 2020
  • Figure 25. BeyondSpring (United States) Revenue, Net Income and Gross profit
  • Figure 26. BeyondSpring (United States) Revenue: by Geography 2020
  • Figure 27. Novartis AG (Switzerand) Revenue, Net Income and Gross profit
  • Figure 28. Novartis AG (Switzerand) Revenue: by Geography 2020
  • Figure 29. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer (United States) Revenue: by Geography 2020
  • Figure 31. Spectrum Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 32. Spectrum Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 33. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 34. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 35. Myelo Therapeutics GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Myelo Therapeutics GmbH (Germany) Revenue: by Geography 2020
  • Figure 37. Global Neutropenia Treatment: by Type USD Million (2021-2026)
  • Figure 38. Global Neutropenia Treatment: by Disease Type USD Million (2021-2026)
  • Figure 39. Global Neutropenia Treatment: by End-users USD Million (2021-2026)
  • Figure 40. Global Neutropenia Treatment: by Distribution Channel USD Million (2021-2026)
  • Figure 41. South America Neutropenia Treatment Share (%), by Country
  • Figure 42. Asia Pacific Neutropenia Treatment Share (%), by Country
  • Figure 43. Europe Neutropenia Treatment Share (%), by Country
  • Figure 44. MEA Neutropenia Treatment Share (%), by Country
  • Figure 45. North America Neutropenia Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Kyowa Hakko Kirin Co., Ltd. (Japan)
  • Cellerant Therapeutics (United States)
  • Mylan N.V. (United States)
  • Amgen (United States(
  • BeyondSpring (United States)
  • Novartis AG (Switzerand)
  • Pfizer (United States)
  • Spectrum Pharmaceuticals (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Myelo Therapeutics GmbH (Germany)
Additional players considered in the study are as follows:
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation